Comparative Efficacy of EGFR-TKI and Combination Therapies

Patients were classified into the EGFR-TKI group and combination therapy group. The patients in EGFR-TKI group received first-, second-, or third- generation EGFR-TKI drugs only. The EGFR-TKI drugs include gefitinib, icotinib, erlotinib, afatinib, dacomitinib, osimertinib, and almonertinib. The patients in the combination group underwent EGFR-TKIs combined with anti-angiogenic drugs or chemotherapy. The antiangiogenic drugs include bevacizumab and anlotinib. The chemotherapy regimens include pemetrexed and carboplatin or cisplatin. There was no direct involvement of human tissues.

Free full text: Click here

Sun H., Ren P., Chen Y., Lan L., Yan Z., Yang Y., Wang B., Wang C., Li Y., Li L., Zhang Y., Li Y., Wang Z., Pan Z, & Jiang Z. (2023). Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. BMC Cancer, 23, 198.

Publication 2023

Afatinib Almonertinib Anlotinib Antiangiogenic drugs Bevacizumab Carboplatin Chemotherapy Cisplatin Combination therapy Dacomitinib Drugs Egfr Erlotinib Gefitinib Human Icotinib Osimertinib Patients Regimens Tissues

Corresponding Organization :

Other organizations : Tianjin Medical University Cancer Institute and Hospital

Top 5 similar protocols

Variable analysis

independent variables

Type of treatment (EGFR-TKI group or combination therapy group)

dependent variables

Clinical outcomes (not explicitly mentioned)

control variables

No direct involvement of human tissues

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!